Results 131 to 140 of about 1,046,440 (397)

The complexities of elexacaftor/tezacaftor/ivacaftor therapeutic drug monitoring in a person with cystic fibrosis and Mycobacterium abscessus pulmonary disease

European Clinical Respiratory Journal
Therapeutic drug monitoring (TDM) of elexacaftor/tezacaftor/ivacaftor (ETI) remains challenging due to a lack of clarity around the parameters that govern ETI plasma concentrations, whilst the use of concomitant CYP3A inducers rifabutin and rifampicin is
Claire Y Mou, Daniel J Henderson, Angela G Matson, Karen M Herd, David W Reid, Timothy Riddles, Ellie Johnson, Brett McWhinney, Rebecca Swenson, Andrew Burke, Ieuan E S Evans   +10 more
doaj   +1 more source

A Novel Tool to Evaluate the Accuracy of Predicting Survival in Cystic Fibrosis [PDF]

arXiv, 2017
Background: Effective allocation of limited donor lungs in cystic fibrosis (CF) requires accurate survival predictions, so that high-risk patients may be prioritized for transplantation. In practice, decisions about allocation are made dynamically, using routinely updated assessments.
arxiv  

Influence of the lung microbiome on antibiotic susceptibility of cystic fibrosis pathogens [PDF]

, 2019
The lungs of patients with cystic fibrosis (CF) are colonised by a microbial community comprised of pathogenic species, such as Pseudomonas aeruginosa and Staphylococcus aureus, and microorganisms that are typically not associated with worse clinical ...
Coenye, Tom, Crabbé, Aurélie, Tavernier, Sarah, Vandeplassche, Eva   +3 more
core   +1 more source

Elexacaftor–Tezacaftor–Ivacaftor Improves Sinonasal Outcomes in Young Children With Cystic Fibrosis

International Forum of Allergy &Rhinology, EarlyView.
ABSTRACT Background Severe chronic rhinosinusitis (CRS) is a near universal manifestation of cystic fibrosis. Elexacaftor/tezacaftor/ivacaftor (ETI) is an oral, small molecule, highly effective Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) corrector–potentiator drug.
Amanda L. Stapleton, Adam Kimple, Jennifer L. Goralski, Daniel M. Beswick, Anshika Gupta, Douglas A. Li, Barton F. Branstetter, S. Mehdi Nouraie, Amber D. Shaffer, Brent Senior, Anna C. Zemke   +10 more
wiley   +1 more source

Worldwide rates of diagnosis and effective treatment for cystic fibrosis.

Journal of Cystic Fibrosis, 2022
Jonathan Guo, A. Garratt, A. Hill
semanticscholar   +1 more source

A CFTR potentiator in patients with cystic fibrosis and the G551D mutation.

New England Journal of Medicine, 2011
BACKGROUND Increasing the activity of defective cystic fibrosis transmembrane conductance regulator (CFTR) protein is a potential treatment for cystic fibrosis.
N. England, M. Bonnie W. Ramsey, M. Jane Davies, N. G. M. Ch.B., Elizabeth Tullis M.D., M. S. C. Bell, Pavel D ř evínek M.D., Matthias Griese M.D., Edward F. McKone M.D., M. C. E. Wainwright, Michael W. Konstan B.S., Richard Moss M.D., Felix Ratjen M.D., Ph. Isabelle Sermet-Gaudelus, Steven M. Rowe Ph.D., Qunming Dong M.S.P.H., Sally Rodriguez Ph.D., M. K. Yen, Claudia Ordoñez M.D., M. J. S. Elborn   +19 more
semanticscholar   +1 more source

Beyond the Lung. Impact of Elexacaftor/Tezacaftor/Ivacaftor on Sinonasal Disease in Children With Cystic Fibrosis

International Forum of Allergy &Rhinology, EarlyView.
ABSTRACT Background Elexacaftor/tezacaftor/ivacaftor (ETI) is a Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) therapy that improves pulmonary function and chronic rhinosinusitis (CRS) in cystic fibrosis (CF) adults with at least one copy of the F508del CFTR mutation.
Margaux Petitjean, Alexia Letierce, Anne‐Sophie Bonnel, Philippe Reix, Eric Deneuville, Nathalie Stremler, Romain Luscan, Vincent Couloigner, Laurent Mely, Katia Bessaci, Guillaume Labbe, Christophe Marguet, Mairead Kelly‐Aubert, Fatiha Hassani, Isabelle Sermet‐Gaudelus, François Simon, the MODUL‐CF Study Group   +16 more
wiley   +1 more source

Using bacterial biomarkers to identify early indicators of cystic fibrosis pulmonary exacerbation onset [PDF]

, 2011
Acute periods of pulmonary exacerbation are the single most important cause of morbidity in cystic fibrosis patients, and may be associated with a loss of lung function.
Bruce, Kenneth D, Carroll, Mary P, Hoffman, Lucas R, Johnson, Matt W, Mayer-Hamblett, Nicole, Rogers, Geraint B, Schwarze, Jürgen   +6 more
core   +1 more source

Restoring Cystic Fibrosis Transmembrane Conductance Regulator Function Reduces Airway Bacteria and Inflammation in People with Cystic Fibrosis and Chronic Lung Infections

American Journal of Respiratory and Critical Care Medicine, 2017
Rationale: Previous work indicates that ivacaftor improves cystic fibrosis transmembrane conductance regulator (CFTR) activity and lung function in people with cystic fibrosis and G551D‐CFTR mutations but does not reduce density of bacteria or markers of
K. B. Hisert, S. Heltshe, C. Pope, P. Jorth, Xia Wu, R. M. Edwards, M. Radey, F. Accurso, D. Wolter, G. Cooke, Ryan J Adam, S. Carter, B. Grogan, J. Launspach, S. Donnelly, C. Gallagher, J. Bruce, D. Stoltz, M. Welsh, L. Hoffman, E. McKone, Pradeep K. Singh   +21 more
semanticscholar   +1 more source

Differential Immune Cell Infiltration in Eosinophilic and Non‐Eosinophilic CRS: Correlations With Clinical, Endoscopic, and Radiological Findings

International Forum of Allergy &Rhinology, EarlyView.
ABSTRACT Background The pathogenesis of inflammation in eosinophilic chronic rhinosinusitis (ECRS) and non‐eosinophilic chronic rhinosinusitis (NECRS) remains poorly understood. This study aimed to assess immune cell infiltration within the sinonasal microenvironment in these conditions.
Katarzyna Czerwaty, Katarzyna Piszczatowska, Mirosław J. Szczepański, Natalia Jermakow, Nils Ludwig, Karolina Dżaman   +5 more
wiley   +1 more source